Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
03 mai 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31,...
Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update
27 avr. 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
CEO and Board Member Dr. Claus Moller has stepped down; Thomas Gad, Founder, Chairman and President assumes Interim CEO role and steps down as Chairman; Dr. Jim Healy to be appointed as...
Y-mAbs Announces Presentation of SADA Technology at AACR
08 avr. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
01 avr. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments
24 févr. 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND...
Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022
17 févr. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December...
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
11 févr. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
UPDATE - Y-mAbs Announces Pipeline Update
15 déc. 2021 09h53 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pipeline Update
15 déc. 2021 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...